Safety and Risk Management in Translational Medicine

Posted:
3
March 2007

Safety and Risk Management in Translational Medicine

"Safety and Risk Management in Translational Medicine"We will be attending and exhibiting at the AGAH – Annual Meeting 2008 in Weimar (Germany) on 18-19 April.This conference focuses on finding appropriate techniques and strategic approaches to improve the safety of study participants, to minimize risk, and to improve the predictive value of the safety profile for a new compound. Concepts and guidelines for the new regulatory environment for Phase 1 studies in the EU will be presented. Experts from all research areas involved will share their experience, discuss the limitations of interpreting the clinical relevance of their studies' results and present concepts for improving the drug development process.Drug development must find a balance between the excitement of discovering new treatment options and the protection of subjects participating in clinical trials. Healthy volunteers and staff responsible for their well being are relying on the adequacy of the procedures applied to minimize risk during the exploratory phases. Hence, the results of pre-clinical pharmacological models, toxicological studies and foregoing clinical trials in healthy volunteers and patients are expected to be a predictive value for the next step. With the increasing number of biologicals and compounds with completely new mechanisms of action this concept may no longer be satisfactory as has been painfully experienced with the first administration of TGN1412 to healthy volunteers.Today's drug development is subjected to a highly regulated and segmented setting. A closer cooperation between pre-clinical and clinical experts is essential to identify and select the appropriate investigational tools, to early identify potential safety issues, and to translate the findings of exploratory trials into efficacious and safe new drugs.We look forward to meeting you at the exhibition. Please visit the Richmond Pharmacology team at our stand to discuss your Early Phase outsourcing requirements.Hotel Registration Form

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more